Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2017 /
Checkmate 067 - combined nivolumab and ipilimumab

1st - 5th Apr 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.04.17
Views: 2023

Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA

Dr Topalian speaks with ecancer at AACR 2017 about the combination of ipilimumab and nivolumab for advanced melanoma.

The results were presented at the conference by Dr James Larkin, and Dr Topalian comments on the response rates and overall survival in the combination.

She considers the prospective value of BRAF and PD-1 biomarkers, and notes a significant increase in trial discontinuation due to adverse events.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation